

Overview: Cohera Medical, Inc.™ aims to fulfill the market demand for a **strong, safe tissue adhesive** by developing a revolutionary line of surgical adhesives and wound management products. Our products are based on a unique chemical design that is purely synthetic, fully resorbable, safe for internal use, easy to use, and generates a very strong bond. The basic chemistry can be formulated for use in a wide variety of surgical applications including plastic surgery, general surgery, and orthopedic surgery. Our lead product under development, **TissuGlu®**, is an easy-to use, resorbable adhesive that positions tissues for optimal healing while minimizing fluid accumulation. Its first target indication is the reduction or elimination of fluid accumulation and the potential for seroma following abdominoplasty procedures.

Problem: Surgeons have expressed a strong need for a product that adheres tissue flaps to help minimize the fluid accumulation (seroma) that occurs between tissue layers after surgery. There are currently no products available that adequately fill this medical need. Available surgical adhesives fall into two main categories: “Superglue”- type products that are strong, but cannot be used inside the body because they break down into toxic by-products, and fibrin sealant products that are used internally, but create a weak bond, are expensive and are difficult to use during surgery. Surgeons seek a product that could encompass the best properties of both products: **easy to use and strong enough to hold tissues together well, as well as biocompatible and resorbable so that the product is safe for internal use.**

Solution: Cohera has developed a revolutionary line of internal surgical adhesives and wound management products. Our lead product, TissuGlu®, is an adhesive for plastic surgery procedures. Unlike “Superglue” products, it is **biocompatible and resorbable, making it safe for internal use.** Unlike fibrin sealant products, it is **strong, easy to use, and contains no human or animal product derivatives.** Studies in the lab have demonstrated that TissuGlu® **virtually eliminates fluid accumulation and the potential for seroma**, one of the most common complications of abdominoplasty and other plastic surgery procedures.

Market: Frost and Sullivan’s 2007 study “US Topical Hemostats and Tissue Sealants” reports that between 2006 and 2013 the market will grow at a compounded annual growth rate (CAGR) of 11.4%, with expected revenues reaching \$1.03 billion in 2013. TissuGlu® will enter the market with an indication in abdominoplasty, a large and growing segment of the plastic surgery market. Future applications could include breast reduction and body contouring, with total annual procedures exceeding 500K.

Patent Status: First patent was issued June '07; second and third formulation patent applications were filed in January '07 and July '07. A spray dispenser design patent application was filed in October '07. A positive 'freedom to operate' opinion was performed. Cohera currently has 36 pending patent applications in the US and abroad.

Funding Status: Series A: \$6.8 million round completed in August 2006 from private investors. Series B: \$16.1 million round completed in October 2008.

Experienced Leadership:

Mr. Patrick Daly (President & CEO) has over 19 years of experience in medical device sales, marketing, international marketing and leadership positions throughout the Johnson & Johnson organization including Ethicon Endo-Surgery, Ethicon Products, J&J Medical Australia/New Zealand, J&J Medical Asia Pacific and Cohera Medical, Inc.

Dr. Eric Beckman (CSO and co-founder) is the primary inventor of the company’s proprietary adhesive technology. He has joined Cohera from his position as George Bevier Professor of Engineering at the University of Pittsburgh’s Department of Chemical Engineering.

Dr. Dottie Clower (VP of Research and Development and Operations) is a neuroscientist and chemist with over 18 years of experience in both industrial and academic environments, including Baxter Healthcare and University of Pittsburgh. Dr. Clower was instrumental in the early formation of the company dating back to 2003.

Mr. Chad Coberly (VP of Clinical, Regulatory, and Legal Affairs) has extensive experience in the medical device industry, primarily in the areas of regulatory/clinical affairs, compliance, quality systems, and general legal affairs. Prior to joining Cohera, he served as the VP of Legal and Regulatory Affairs for Zass Medical Evolutions, and worked at Stryker Corporation in both regulatory and legal positions.

Mr. Rich Wonsettler (VP of Finance, CFO) has served as a financial executive and consultant for private and publicly traded companies in the services and technology industries. He has nearly 20 years of financial management experience with emerging private and public companies.

Mr. William Cotter (VP of Manufacturing) has over 29 years of manufacturing and operations experience in the medical device, diagnostic, biologics and life science industries and has extensive industry knowledge guiding product manufacturing from early-stage R&D through worldwide commercialization.

Regulatory Status: In pre-clinical studies, TissuGlu® has demonstrated the virtual elimination of post operative fluid accumulation and seroma (**Plastic and Reconstructive Surgery, July 2008**). No foreign body reaction or adverse tissue responses were found in this study. TissuGlu® has passed all critical biocompatibility tests to establish safety in preparation for entry into human clinical trials.